Biopharma Quarterly Dealmaking Statistics, Q2 2018
A look at financing, M&A and alliance activity April–June 2018
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.
You may also be interested in...
Emerging Company Profile: Brii Bio has been set up in Shanghai with robust initial funding and a handful of founding partnerships to help in its goal of accelerating innovation and optimizing access to the latest medicines for Chinese patients, with a focus on treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung disorders.
Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.
Genentech is to work with microbiome therapeutics company Microbiotica in a collaboration to discover, develop and commercialise treatments for inflammatory bowel disease.